Gabriela Dieguez, FSA, MAAA, Amy W. Law, PharmD, Richard Lynen, MD, James Trussell, PhD, Bruce Pyenson, FSA, MAAA
Pregnancy is associated with a significant cost for employers providing health insurance benefits to their employees. The latest study on the topic was published in 2002, estimating the unintended pregnancy rate for women covered by employer-sponsored insurance benefits to be approximately 29%.
A Call to Action to Address Burden of Unintended Pregnancies in Plans’ Benefit Design
Budgetary Impact of Adding Riociguat to a US Health Plan for the Treatment of Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension
Chakkarin Burudpakdee, PharmD, Anshul Shah, MS, Vijay N Joish, PhD, Christine H. Divers, PhD, Avin Yaldo, PhD
Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), the 2 subtypes of pulmonary hypertension, are chronic, debilitating, and life-threatening conditions.
Is It Time for Risk-Sharing Contracts In Specialty Pharmacy?
Impact of the New ACC/AHA Guidelines on the Treatment of High Blood Cholesterol in a Managed Care Setting
Paul S Chan, MD, MSc, Heidi C. Lew, PharmD, Toros Cagla PhD, Brian K. Solow, MD, FAAFP, Karen M. Stockl, PharmD, Josephine N. Tran, PharmD, MS
In November 2013, the American College of Cardiology (ACC) and the American Heart Association (AHA) released together new clinical guidelines for the treatment of patients with high blood cholesterol. The 2013 guidelines provide a new paradigm for cholesterol management in the primary and secondary prevention of coronary artery disease (CAD)
Real-World Consequences of the 2013 ACC/AHA Cholesterol Guidelines for the Prevention of Cardiovascular Disease
Healthcare Costs Among Patients with Excessive Sleepiness Associated with Obstructive Sleep Apnea, Shift Work Disorder, or Narcolepsy
Rashad Carlton, PharmD, MSPH, Cathryn A. Carroll, PhD, Orsolya Lunacsek, PhD, Timothy S. Regan, BPharm, RPh, CPh
Excessive daytime sleepiness affects nearly 20% of the general population and is associated with many medical conditions, including shift work disorder (SWD), obstructive sleep apnea (OSA), and narcolepsy. Excessive sleepiness imposes a significant clinical, quality-of-life, safety, and economic burden on society.
Out-of-Pocket Cost of Therapy Can Affect Patients’ Excessive Sleepiness and Daytime Functioning
Lessons from the Leucovorin Shortages Between 2009 and 2012 in a Medicare Advantage Population: Where Do We Go from Here?
Three distinct shortages of the generic drug leucovorin, a reduced form of folic acid used in several chemotherapy regimens, were reported by the US Food and Drug Administration (FDA) between 2008 and 2014. Levoleucovorin, an alternative therapy to leucovorin, failed to demonstrate superiority over leucovorin in clinical trials and is substantially more expensive.
Drug Shortages Are Costly to Patients and to Payers
Counterfeit drugs comprise an increasing percentage of the US drug market and even a larger percentage in less developed countries. Counterfeit drugs involve both lifesaving and lifestyle drugs.
The Hidden Market of Counterfeit Drugs a Concern for All Stakeholders
The Economic Burden of Ischemic Stroke and Major Hemorrhage in Medicare Beneficiaries with Nonvalvular Atrial Fibrillation: A Retrospective Claims Analysis
Understanding the economic implications of oral anticoagulation therapy requires careful consideration of the risks and costs of stroke and major hemorrhage. The majority of patients with atrial fibrillation (AF) are aged ≥65 years, so focusing on the Medicare population is reasonable when discussing the risk for stroke.
The Clinical Toll of Nonvalvular Atrial Fibrillation Poses Significant Economic Burden
The Impact of 5-HT3RA Use on Cost and Utilization in Patients with Chemotherapy- Induced Nausea and Vomiting: Systematic Review of the Literature
Michael S. Broder, MD, MSHS, Claudio Faria, PharmD, MPH, Annette Powers, PharmD, MBA, Jehangeer Sunderji, MD, Dasha Cherepanov, PhD
Individual studies have assessed the impact of standard prophylactic therapy with 5-hydroxytryptamine receptor antagonists (5-HT3RAs) for chemotherapy-induced nausea and vomiting (CINV) on cost and utilization, but no synthesis of the findings exists.
The Value of Pharmaceuticals in the Prevention and Treatment of CINV
The demand for economic models that evaluate cancer treatments is increasing, as healthcare decision makers struggle for ways to manage their budgets while providing the best care possible to patients with cancer. Yet, after nearly 2 decades of cultivating and refining techniques for modeling the cost-effectiveness and budget impact of cancer therapies, serious methodologic and policy challenges have emerged that question the adequacy of economic modeling as a sound decision-making tool in oncology.
Disruptive Innovation, Uncertain Value, and Economic Modeling in Oncology
Christopher M. Blanchette, PhD, MBA, Nicholas J. Gross, MD, PhD, Pablo Altman, MD, MBA, F. Randy Vogenberg, RPh, PhD
The clinical and economic burden of chronic obstructive pulmonary disease (COPD) is significant and is increasing. COPD is now the third leading cause of death in the United States, after heart disease and cancer. COPD reached this rank in 2008, more than a decade earlier than projected by the Global Burden of Disease Study. In the United States, mortality due to COPD is the only one among the 5 leading causes of death that showed an increasing rate between 2010 and 2011.
Chronic Obstructive Pulmonary Disease Remains a Growing Population Health Concern
Page 4 of 11
Results 31 - 40 of 106
Results 31 - 40 of 106